vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and VICOR CORP (VICR). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $113.0M, roughly 1.6× VICOR CORP). VICOR CORP runs the higher net margin — 18.3% vs 13.3%, a 5.0% gap on every dollar of revenue. On growth, VICOR CORP posted the faster year-over-year revenue change (20.2% vs -1.8%). Over the past eight quarters, VICOR CORP's revenue compounded faster (14.7% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Vicor Corporation is a manufacturer of power modules headquartered in Andover, Massachusetts.
AMPH vs VICR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $113.0M |
| Net Profit | $24.4M | $20.7M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 59.7% |
| Net Margin | 13.3% | 18.3% |
| Revenue YoY | -1.8% | 20.2% |
| Net Profit YoY | -35.7% | 713.9% |
| EPS (diluted) | $0.51 | $0.44 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.0M | ||
| Q4 25 | $183.1M | $107.3M | ||
| Q3 25 | $191.8M | $110.4M | ||
| Q2 25 | $174.4M | $96.0M | ||
| Q1 25 | $170.5M | $94.0M | ||
| Q4 24 | $186.5M | $96.2M | ||
| Q3 24 | $191.2M | $93.2M | ||
| Q2 24 | $182.4M | $85.9M |
| Q1 26 | — | $20.7M | ||
| Q4 25 | $24.4M | $46.5M | ||
| Q3 25 | $17.4M | $28.3M | ||
| Q2 25 | $31.0M | $41.2M | ||
| Q1 25 | $25.3M | $2.5M | ||
| Q4 24 | $38.0M | $10.2M | ||
| Q3 24 | $40.4M | $11.6M | ||
| Q2 24 | $37.9M | $-1.2M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | 55.4% | ||
| Q3 25 | 51.4% | 57.5% | ||
| Q2 25 | 49.6% | 95.9% | ||
| Q1 25 | 50.0% | 47.2% | ||
| Q4 24 | 46.5% | 52.4% | ||
| Q3 24 | 53.3% | 49.1% | ||
| Q2 24 | 52.2% | 49.8% |
| Q1 26 | — | 59.7% | ||
| Q4 25 | 19.4% | 14.6% | ||
| Q3 25 | 13.2% | 18.9% | ||
| Q2 25 | 24.2% | 47.3% | ||
| Q1 25 | 21.9% | -0.2% | ||
| Q4 24 | 24.2% | 9.6% | ||
| Q3 24 | 29.8% | 5.8% | ||
| Q2 24 | 30.3% | 0.2% |
| Q1 26 | — | 18.3% | ||
| Q4 25 | 13.3% | 43.4% | ||
| Q3 25 | 9.0% | 25.6% | ||
| Q2 25 | 17.8% | 42.9% | ||
| Q1 25 | 14.8% | 2.7% | ||
| Q4 24 | 20.4% | 10.7% | ||
| Q3 24 | 21.1% | 12.4% | ||
| Q2 24 | 20.8% | -1.4% |
| Q1 26 | — | $0.44 | ||
| Q4 25 | $0.51 | $1.01 | ||
| Q3 25 | $0.37 | $0.63 | ||
| Q2 25 | $0.64 | $0.91 | ||
| Q1 25 | $0.51 | $0.06 | ||
| Q4 24 | $0.74 | $0.24 | ||
| Q3 24 | $0.78 | $0.26 | ||
| Q2 24 | $0.73 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $404.2M |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $754.1M |
| Total Assets | $1.6B | $804.9M |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $404.2M | ||
| Q4 25 | $282.8M | $402.8M | ||
| Q3 25 | $276.2M | $362.4M | ||
| Q2 25 | $231.8M | $338.5M | ||
| Q1 25 | $236.9M | $296.1M | ||
| Q4 24 | $221.6M | $277.3M | ||
| Q3 24 | $250.5M | $267.6M | ||
| Q2 24 | $217.8M | $251.9M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $754.1M | ||
| Q4 25 | $788.8M | $711.6M | ||
| Q3 25 | $776.7M | $630.1M | ||
| Q2 25 | $757.5M | $608.6M | ||
| Q1 25 | $751.3M | $580.3M | ||
| Q4 24 | $732.3M | $570.1M | ||
| Q3 24 | $727.7M | $554.6M | ||
| Q2 24 | $713.3M | $537.2M |
| Q1 26 | — | $804.9M | ||
| Q4 25 | $1.6B | $785.8M | ||
| Q3 25 | $1.7B | $710.2M | ||
| Q2 25 | $1.6B | $693.5M | ||
| Q1 25 | $1.6B | $665.0M | ||
| Q4 24 | $1.6B | $641.1M | ||
| Q3 24 | $1.5B | $632.8M | ||
| Q2 24 | $1.5B | $613.2M |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | — |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $15.7M | ||
| Q3 25 | $52.6M | $38.5M | ||
| Q2 25 | $35.6M | $65.2M | ||
| Q1 25 | $35.1M | $20.1M | ||
| Q4 24 | $29.0M | $10.1M | ||
| Q3 24 | $60.0M | $22.6M | ||
| Q2 24 | $69.1M | $15.6M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $10.2M | ||
| Q3 25 | $47.2M | $34.5M | ||
| Q2 25 | $25.0M | $59.0M | ||
| Q1 25 | $24.4M | $15.6M | ||
| Q4 24 | $16.6M | $8.4M | ||
| Q3 24 | $46.2M | $14.1M | ||
| Q2 24 | $63.1M | $9.4M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 9.5% | ||
| Q3 25 | 24.6% | 31.2% | ||
| Q2 25 | 14.3% | 61.5% | ||
| Q1 25 | 14.3% | 16.6% | ||
| Q4 24 | 8.9% | 8.7% | ||
| Q3 24 | 24.1% | 15.2% | ||
| Q2 24 | 34.6% | 11.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 5.2% | ||
| Q3 25 | 2.8% | 3.6% | ||
| Q2 25 | 6.1% | 6.5% | ||
| Q1 25 | 6.3% | 4.8% | ||
| Q4 24 | 6.7% | 1.8% | ||
| Q3 24 | 7.2% | 9.1% | ||
| Q2 24 | 3.3% | 7.2% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 0.34× | ||
| Q3 25 | 3.03× | 1.36× | ||
| Q2 25 | 1.15× | 1.58× | ||
| Q1 25 | 1.39× | 7.93× | ||
| Q4 24 | 0.76× | 0.99× | ||
| Q3 24 | 1.48× | 1.95× | ||
| Q2 24 | 1.82× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
VICR
| Product revenue | $98.0M | 87% |
| Royalty revenue | $15.0M | 13% |
